Income statement

For Bionano Genomics Inc., the income statement review should cover revenue, mix, gross profit and operating expenses. The production version must cite current primary disclosures and retain an as-of date for facts that can change. The purpose of this section is to connect evidence to a decision-relevant interpretation rather than reproduce management language.

Balance sheet

For Bionano Genomics Inc., the balance sheet review should cover liquidity, leverage, working capital and sector-specific assets or liabilities. The production version must cite current primary disclosures and retain an as-of date for facts that can change. The purpose of this section is to connect evidence to a decision-relevant interpretation rather than reproduce management language.

Cash flow

For Bionano Genomics Inc., the cash flow review should cover operating cash conversion, capex and free cash flow. The production version must cite current primary disclosures and retain an as-of date for facts that can change. The purpose of this section is to connect evidence to a decision-relevant interpretation rather than reproduce management language.

KPI discipline

For Bionano Genomics Inc., the kpi discipline review should cover management-defined non-GAAP and operating metrics must be reconciled and dated. The production version must cite current primary disclosures and retain an as-of date for facts that can change. The purpose of this section is to connect evidence to a decision-relevant interpretation rather than reproduce management language.

Research Checklist

  • Organic Revenue Growth - For Bionano Genomics Inc. (BNGO), determine from current primary sources whether organic revenue growth is a material financial metrics; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
  • Orders And Book-To-Bill Where Relevant - For Bionano Genomics Inc. (BNGO), determine from current primary sources whether orders and book-to-bill where relevant is a material financial metrics; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
  • Backlog - For Bionano Genomics Inc. (BNGO), determine from current primary sources whether backlog is a material financial metrics; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
  • Segment Margin - For Bionano Genomics Inc. (BNGO), determine from current primary sources whether segment margin is a material financial metrics; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
  • Price/Cost Spread - For Bionano Genomics Inc. (BNGO), determine from current primary sources whether price/cost spread is a material financial metrics; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
  • Capacity Utilization - For Bionano Genomics Inc. (BNGO), determine from current primary sources whether capacity utilization is a material financial metrics; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
  • Working Capital - For Bionano Genomics Inc. (BNGO), determine from current primary sources whether working capital is a material financial metrics; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
  • Capital Expenditures - For Bionano Genomics Inc. (BNGO), determine from current primary sources whether capital expenditures is a material financial metrics; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
  • Free Cash Flow - For Bionano Genomics Inc. (BNGO), determine from current primary sources whether free cash flow is a material financial metrics; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.
  • Return On Invested Capital - For Bionano Genomics Inc. (BNGO), determine from current primary sources whether return on invested capital is a material financial metrics; document the evidence, direction of change, and why it matters to revenue, margins, cash flow or balance-sheet resilience.

Source Standard

Use the latest annual report, quarterly filings, material 8-Ks and official investor-relations disclosures before publication. Do not infer company-specific figures from the sector framework.